

LivaNova

Health innovation that matters

Our Mission

At LivaNova, we unite to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart.

We address patients' and providers' critical needs by improving quality of life, safety and access while reducing complications, hospitalization and cost.



Our Strategic Focus


- **Serve** patients around the world
- **Deliver** digitally integrated products and services
- **Build and sustain** superior relationships with customers

Worldwide Footprint

Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs approximately 2,900 employees.

Proforma revenues by geography based on full-year 2023 net sales:

US: 55% **EU: 19%** **ROW: 26%**



The Markets We Serve

Listed on NASDAQ stock exchange as **LIVN**

NEUROMODULATION
Creator, leader of VNS Therapy™
* Sales \$520M
Disease States <ul style="list-style-type: none"> • Drug-resistant epilepsy • Difficult-to-treat depression • Obstructive sleep apnea
Customers <ul style="list-style-type: none"> • Neurologists • Epileptologists • Psychiatrists • Neurosurgeons • ENT Specialists

CARDIOPULMONARY
Market-leading positions
* Sales \$589M
Disease States <ul style="list-style-type: none"> • Coronary artery disease • Congenital heart defect • Atrial fibrillation • Valvular disease
Customers <ul style="list-style-type: none"> • Perfusionists • Intensivists • Cardiac Surgeons • Cardiologists • Interventional Cardiologists

* Sales based on full-year 2023. Numbers may not add precisely due to rounding

EPILEPSY*

SenTiva™

Enhanced programming features, customizable treatment and therapy management while patients live their lives

135,000+ patients treated with VNS Therapy worldwide



CARDIOPULMONARY*

Essenz Perfusion System designed to meet the modern needs of the New Era of Perfusion

Built on a **50-year legacy** of safety and reliability



CARDIOPULMONARY*

Inspire™ Oxygenator

personalized perfusion – safe, easy and flexible for all adult patient sizes

3.5+ million patients treated to date



XTRA™ Autotransfusion System

lowers the transfusion rates during and after cardiac surgery^{1,2}

4+ million patients treated per year



Strategic Portfolio Initiatives*

LivaNova has a differentiated pipeline targeting medical conditions with high unmet needs:

- **Difficult-to-Treat Depression (DTD):** VNS Therapy shows a significant improvement in quality of life and provides long-term protection from depressive symptoms.
- **Obstructive Sleep Apnea (OSA):** The therapy consists of an innovative, CPAP alternative, fully implantable device called the aura6000™. Specifically designed to reduce or eliminate moderate to severe sleep apnea.

Improving quality of life for patients worldwide

LivaNova
Health innovation that matters



www.livanova.com

20 Eastbourne Terrace
London, W2 6LG, United Kingdom
+1 281-895-2382

*Products not approved in all geographies. Consult your labeling. Click appropriate links to access safety information: VNS Therapy-Epilepsy (US); VNS Therapy-Epilepsy (OUS); Essenz Perfusion System; INSPIRE Oxygenator; XTRA ATS; VNS Therapy-Depression (US); VNS Therapy-Depression (OUS) and OSA. For OSA – caution: limited by United States law to investigational use. 1.Vonk et al. Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort study. Transfusion. 2013 Nov;53(11):2782-9. | 2.Côté et al. Efficacy of intraoperative cell salvage in decreasing perioperative blood transfusion rates in first-time cardiac surgery patients: a retrospective study. Can J Surg 2016 Sep;59(5):330-6.